InvestSMART

Medical Developments International Limited (ASX:MVP)

ALERT: Price-sensitive ASX Announcement for MVP
Current share price for MVP : $0.485 0.03 (6.59%)+
Announcement
Release
19 Feb 2026 8:55AM
Price at Release
$0.455
Full Release
download
Summary
Medical Developments International Limited (MVP) reported its FY26 Half Year results, highlighting significant progress in its strategic execution. The company achieved positive cash flow from operations and reported a revenue increase of 8% to $21.6 million compared to the previous corresponding period. A key focus was on the growth of its lead product, Penthrox, with a 26% increase in volume in the Australian hospital segment and a 10% increase in European markets. Notably, Penthrox's eligibility in the Pharmaceutical Benefits Scheme's Prescriber Bag was expanded to include Nurse Practitioners in Australia. Despite a loss of $0.2 million net after tax, MVP emphasized maintaining cost discipline and continued efforts to expand the market for Penthrox, including ongoing regulatory approvals for pediatric use in Europe. The company anticipates finalizing these approvals by August 2026, further broadening its market reach.
Key Points
  • Positive cashflow from operating activities for FY26 half year.
  • Penthrox revenue up by $2.3 million.
  • Penthrox volume growth of 26% in the Australian hospital segment.
  • Penthrox European volume growth of 10%.
  • Expanded PBS Prescriber Bag eligibility to Nurse Practitioners in Australia.
  • MAGPIE paediatric study published, supporting Penthrox's paediatric use.
  • Health economic study completed demonstrating cost savings with Penthrox.
  • Cash balance as of 31 December 2025 was $16.9 million.
  • Net loss after tax was $0.2 million for the half year.
  • Continued focus on expanding Penthrox's market and regulatory approvals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.